Camp4 Therapeutics annual net profit margin
2023
2024
2025
Camp4 Therapeutics Net Profit Margin Growth & History (CAMP)
Camp4 Therapeutics's net profit margin was −2,298.54% for fiscal 2025.
View full Camp4 Therapeutics company overviewCamp4 Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −2,298.54% | +5644.86 pp |
| 2024 | 2024-12-31 | −7,943.40% | +6139.74 pp |
| 2023 | 2023-12-31 | −14,083.14% | — |
Camp4 Therapeutics quarterly net profit margin
Q3.23
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −1,884.77% | −1043.95 pp |
| Q1 2026 | 2026-03-31 | −1,416.62% | +32.45 pp |
| Q4 2025 | 2025-12-31 | −11,575.86% | −9539.21 pp |
| Q3 2025 | 2025-09-30 | −1,899.25% | — |
| Q2 2025 | 2025-06-30 | −840.81% | — |
| Q1 2025 | 2025-03-31 | −1,449.07% | — |
| Q4 2024 | 2024-12-31 | −2,036.66% | — |
| Q3 2023 | 2023-09-30 | −3,341.71% | — |
Camp4 Therapeutics net profit margin trends
Between the periods ended 2023-12-31 and 2025-12-31, Camp4 Therapeutics's net profit margin increased from −14,083.14% to −2,298.54%, a change of +11784.60 percentage points. The latest reported quarter, Q2 2026, shows −1,884.77%.
About the metric
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
Calculation and source
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Camp4 Therapeutics source filings ↗Community posts
CAMP4 receives UK authorization for its first SYNGAP1 clinical study
CAMP4 Therapeutics ($CAMP) received UK authorization to include sites in its global Phase 1/2 study of CMP002, an investigational treatment for SYNGAP1-related disorder. The decision follows earlier clearances in Australia and Argentina, wh ...